Condensed azepines as vasopressin agonists
This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V 1 and V 2 are both H, OMe or F, or one of V 1 and V 2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N 3 , NH 2 , NHBn or NH-acyl and the other is H, or V 1 and V 2 together are ═O, —O(CH 2 ) p O— or —S(CH 2 ) p S—; W 1 is either O or S; X 1 and X 2 are both H, or together are ═O or ═S; Y is OR 5 or NR 6 R 7 ; R 1 , R 2 , R 3 and R 4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br; R 5 is selected from H and lower alkyl; R 6 and R 7 are independently selected from H and lower alkyl, or together are —(CH 2 ) n —; n=3, 4, 5, 6; and p is 2 or 3. The compounds are agonists at the vasopressin V2 receptor and are useful as antidiuretics and procoagulants. The invention further comprises pharmaceutical compositions incorporating these vasopressin agonists, which compositions are particularly useful in the treatment of central diabetes insipidus, nocturnal enuresis and nocturia.
1. A compound according to formula 1, or a pharmaceutically acceptable salt thereof,
wherein:
A is a benzazepine ring as follows
and wherein
A 16 and A 17 are both CH 2 ;
Z is —CH═CH—;
V 1 and V 2 are both H, OMe or F, or one of V 1 and V 2 is OH, OMe, OBn, OPh, O-acyl, Br, Cl, F, N 3 , NH 2 , NHBn or NH-acyl and the other is H, or V 1 and V 2 together are ═O, —S(CH 2 ) p S— or —O(CH 2 ) p O—;
W 1 is either O or S;
X 1 and X 2 are both H, or together are ═O or ═S;
Y is OR 5 or NR 6 R 7 ;
R 1 , R 2 , R 3 , and R 4 are independently selected from H, lower alkyl, lower alkyloxy, F, Cl and Br;
R 5 is selected from H and lower alkyl;
R 6 and R 7 are independently selected from H and lower alkyl, or together are —(CH 2 ) n —;
n=3, 4, 5 or 6; and
p=2 or 3.
2. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein one of R 1 and R 2 is Cl or Me and the other is H, and both R 3 and R 4 are H.
3. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein one of V 1 and V 2 is OMe or OBn and the other is H.
4. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 together are ═O and Y is NR 6 R 7 .
5. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is
wherein
W 1 is either O or S;
one of R a and R b is Cl or methyl and the other is H;
R c is methyl or benzyl;
R 6 and R 7 are independently selected from H and lower alkyl, or together are —(CH 2 ) n —; and
n is 3, 4, 5 or 6.
6. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is
wherein
W 1 is either O or S;
one of R a and R b is Cl or methyl and the other is H;
R c is methyl or benzyl; and
R 6 and R 7 are independently selected from H and lower alkyl, or together are —(CH 2 ) n —; and
n is 3, 4, 5 or 6.
7. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein V 1 and V 2 are both H.
8. A compound according to claim 7 , or a pharmaceutically acceptable salt thereof, wherein X 1 and X 2 together are ═O and Y is NR 6 R 7 .
9. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is
wherein
W 1 is either O or S;
one of R a and R b is Cl or methyl and the other is H;
R 6 and R 7 are independently selected from H and lower alkyl, or together are —(CH 2 ) n —; and
n is 3, 4, 5, or 6.
10. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, which is
wherein
W 1 is either O or S;
one of R a and R b is Cl or methyl and the other is H;
R 6 and R 7 are independently selected from H and lower alkyl, or together are —(CH 2 ) n —; and
n is 3, 4, 5 or 6.
11. A compound according to claim 1 , which is selected from the group consisting of
1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-4-hydroxy-1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-1-(3-chloro-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-4-methoxy-L-proline-N,N-dimethylamide,
(4R)-1-(2-chloro-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-4-methoxy-L-proline-N,N-dimethylamide,
(4R)-4-benzyloxy-1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-4-methoxy-1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
(4R)-4-methoxy-1-(3-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzylcarbamoyl)-L-proline-N,N-dimethylamide,
or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition which contains active agent selected from compounds and pharmaceutically acceptable salts according to claim 1 .
13. A method of treatment of a condition selected from the group consisting of nocturnal enuresis, nocturia and central diabetes insipidus, which method comprises the administration to a person in need of such treatment of an effective amount of a composition according to claim 12 .
14. A method for the control of urinary incontinence, which method comprises the administration to a person in need of such treatment of an effective amount of a composition according to claim 12 .
15. A method of treatment according to claim 14 , wherein the treatment results in voiding postponement.
16. A method of treatment of bleeding disorders, which method comprises the administration to a person in need of such treatment of an effective amount of a composition according to claim 12 .